Frazier Life Sciences Management L.P. cut its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 75.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 397,483 shares of the company’s stock after selling 1,192,448 shares during the quarter. Frazier Life Sciences Management L.P.’s […]
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12-month price […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target boosted by Robert W. Baird from $52.00 to $62.00 in a research note issued to investors on Thursday, Benzinga reports. They currently have an outperform rating on the stock. A number of other equities research analysts have also recently commented on CRNX. Oppenheimer raised their […]
HC Wainwright reissued their buy rating on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Thursday, Benzinga reports. The firm currently has a $60.00 price target on the stock. A number of other equities analysts also recently weighed in on the company. JMP Securities reiterated a market […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price target increased by Morgan Stanley from $50.00 to $70.00 in a research note released on Thursday, Benzinga reports. They currently have an overweight rating on the stock. Other analysts also recently issued research reports about the stock. Robert W. Baird raised their price target on shares […]